Drugs

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

Photo from Rami Manochakian/X

Apr 26, 2024, 10:07

Rami Manochakian: U.S. FDA approves adjuvant Alectinib in patients with stage IB-IIIA ALK+Non-Small Cell Lung Cancer

Rami Manochakian, Associate Professor and Thoracic Oncologist at Mayo Clinic, shared on X/Twitter:

”HOT OFF THE PRESS.

BIG NEWS.

U.S. FDA approves adjuvant Alectinib following surgery in patients with stage IB-IIIA ALK+ Non-Small Cell Lung Cancer based on results of Alina trial:

High DFS HR: 0.24 (compared with adjuvant chemotherapy).”

Read further.
Source: Rami Manochakian/X

adjucant alectinib alectinib ALINA trial ALK Positive Lung CancerK cancer Cancer research chemotherapy clinical trial FDA approval Lung cancer Mayo Clinic non small cell lung cancer NSCLC OncoDaily Oncology Rami Manochakian U.S. FDA

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage